Gossamer Bio, Inc. (GOSS) NASDAQ
$0.91 (0.05) (-5.28%)
Market Cap: $205.87M
As of 09/06/24 04:00 PM EDT. Market closed.
Gossamer Bio, Inc. (GOSS)
NASDAQ
$0.91
(0.05) (-5.28%)
Market Cap: $205.87M
As of 09/06/24 04:00 PM EDT. Market closed.
Add to Portfolio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT ... read more
COMPANY PROFILE
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Faheem Hasnain
Full Time Employees
135
CEO Compensation (Base)
$606,901
CEO Compensation (Total)
$2.10M
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Faheem Hasnain
Full Time Employees
135
CEO Compensation (Base)
$606,901
CEO Compensation (Total)
$2.10M
Address
3013 Science Park Road, CA, San Diego, 92121.
PRICE CHART FOR GOSSAMER BIO, INC.
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.97
Previous Close
$0.96
Days Range
$0.88 - $0.97
52 week range
$0.45 - $1.60
Volume
747,958
Avg. Volume (30 days)
2,066,533
Market Cap
$205.87M
Dividend Yield
-
P/E
(4.79)
Shares Outstanding
226,227,000
Open
$0.97
Previous Close
$0.96
Days Range
$0.88 - $0.97
52 week range
$0.45 - $1.60
Volume
747,958
Avg. Volume (30 days)
2,066,533
Market Cap
$205.87M
Dividend Yield
-
P/E
(4.79)
Shares Outstanding
226,227,000
FINANCIAL STATEMENTS FOR GOSSAMER BIO, INC.
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR GOSSAMER BIO, INC.
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Aranda Richard | Chief Medical Officer | Jun 24, 2024 | Sale | $0.66 | 1,908 | 1,260 | 196,891 | Jun 25, 2024, 06:24 PM |
| Hasnain Faheem | President & CEO | Jun 21, 2024 | Buy | $0.67 | 372,000 | 250,282 | 5,408,073 | Jun 24, 2024, 05:52 PM |
| Giraudo Bryan | COO/CFO | Jun 18, 2024 | Buy | $0.59 | 100,000 | 59,110 | 480,010 | Jun 20, 2024, 08:21 PM |
| Smith Robert Paul JR | Chief Commercial Officer | Jun 17, 2024 | Buy | $0.60 | 25,000 | 15,050 | 25,000 | Jun 20, 2024, 08:20 PM |
| Christian Waage | EVP, Tech Ops and Admin | Mar 27, 2024 | Sale | $1.16 | 6,430 | 7,430 | 585,934 | Mar 28, 2024, 06:16 PM |
| Giraudo Bryan | COO/CFO | Mar 27, 2024 | Sale | $1.16 | 6,430 | 7,431 | 92,737 | Mar 28, 2024, 06:05 PM |
| Hasnain Faheem | President & CEO | Mar 27, 2024 | Sale | $1.16 | 23,172 | 26,773 | 120,293 | Mar 28, 2024, 06:01 PM |
| Aranda Richard | Chief Medical Officer | Mar 18, 2024 | Sale | $1.33 | 4,018 | 5,342 | 198,799 | Mar 19, 2024, 06:50 PM |
| Peterson Caryn | EVP, Regulatory Affairs | Mar 18, 2024 | Sale | $1.33 | 4,018 | 5,343 | 49,833 | Mar 19, 2024, 06:50 PM |
| Milligan Sandra | Director | Nov 15, 2023 | Buy | $0.79 | 32,000 | 25,213 | 32,000 | Nov 17, 2023, 04:01 PM |
| Giraudo Bryan | COO/CFO | Nov 13, 2023 | Buy | $0.56 | 200,000 | 112,880 | 380,010 | Nov 14, 2023, 06:24 PM |
| Giraudo Bryan | COO/CFO | Jul 24, 2023 | Option Exercise | $1.82 | 54,020 | 98,316 | 180,010 | Jul 26, 2023, 04:03 PM |
| Hasnain Faheem | President & CEO | Jul 24, 2023 | Option Exercise | $1.82 | 540,176 | 983,120 | 5,036,073 | Jul 26, 2023, 04:02 PM |
| Christian Waage | EVP, Tech Ops and Admin | Jul 24, 2023 | Option Exercise | $1.82 | 13,504 | 24,577 | 45,892 | Jul 26, 2023, 04:01 PM |
| Aranda Richard | Chief Medical Officer | Jun 22, 2023 | Sale | $1.29 | 1,814 | 2,340 | 197,574 | Jun 26, 2023, 04:01 PM |
| Giraudo Bryan | COO/CFO | Apr 04, 2023 | Buy | $1.02 | 55,000 | 56,094 | 125,990 | Apr 05, 2023, 04:26 PM |
| Christian Waage | EVP, Tech Ops and Admin | Mar 20, 2023 | Buy | $1.20 | 18,500 | 22,145 | 32,388 | Mar 22, 2023, 05:19 PM |
| Giraudo Bryan | COO/CFO | Mar 20, 2023 | Buy | $0.97 | 50,000 | 48,435 | 70,990 | Mar 22, 2023, 05:17 PM |
| Hasnain Faheem | President & CEO | Mar 20, 2023 | Buy | $1.03 | 168,683 | 174,486 | 3,786,008 | Mar 22, 2023, 05:14 PM |
| Hasnain Faheem | President & CEO | Mar 22, 2023 | Buy | $1.14 | 440,500 | 503,580 | 4,495,897 | Mar 22, 2023, 05:14 PM |
| Hasnain Faheem | President & CEO | Mar 21, 2023 | Buy | $1.20 | 269,389 | 322,324 | 4,055,397 | Mar 22, 2023, 05:14 PM |
| Carter Laura | Chief Scientific Officer | Mar 16, 2023 | Sale | $1.10 | 6,029 | 6,620 | 76,263 | Mar 20, 2023, 09:22 AM |
| Aranda Richard | Chief Medical Officer | Mar 16, 2023 | Sale | $1.10 | 7,563 | 8,304 | 199,388 | Mar 20, 2023, 09:21 AM |
| Peterson Caryn | EVP, Regulatory Affairs | Mar 16, 2023 | Sale | $1.10 | 7,564 | 8,305 | 53,851 | Mar 20, 2023, 09:19 AM |
| Carter Laura | Chief Scientific Officer | Oct 24, 2022 | Sale | $12.07 | 4,876 | 58,868 | 82,292 | Oct 27, 2022, 05:04 PM |
| Peterson Caryn | EVP, Regulatory Affairs | Oct 24, 2022 | Sale | $12.07 | 4,757 | 57,431 | 61,415 | Oct 25, 2022, 04:59 PM |
| Carter Laura | Chief Scientific Officer | Oct 24, 2022 | Sale | $12.07 | 4,876 | 58,868 | 82,292 | Oct 25, 2022, 04:57 PM |
| Aranda Richard | Chief Medical Officer | Oct 24, 2022 | Sale | $12.07 | 4,757 | 57,431 | 205,430 | Oct 25, 2022, 04:55 PM |
| Carter Laura | Chief Scientific Officer | Jul 15, 2022 | Buy | $7.21 | 6,934 | 49,994 | 87,168 | Jul 15, 2022, 04:27 PM |
| Christian Waage | EVP, Tech Ops and Admin | Jul 15, 2022 | Buy | $7.21 | 6,934 | 49,994 | 13,888 | Jul 15, 2022, 04:25 PM |
| Giraudo Bryan | COO/CFO | Jul 15, 2022 | Buy | $7.21 | 13,869 | 99,995 | 20,990 | Jul 15, 2022, 04:23 PM |
| Hasnain Faheem | President & CEO | Jul 15, 2022 | Buy | $7.21 | 138,696 | 999,998 | 3,617,325 | Jul 15, 2022, 04:21 PM |
| Carter Laura | Chief Scientific Officer | Jul 01, 2022 | Sale | $8.25 | 8,808 | 72,648 | 80,234 | Jul 05, 2022, 04:39 PM |
| Aranda Richard | Chief Medical Officer | Jun 22, 2022 | Sale | $6.88 | 1,778 | 12,233 | 209,897 | Jun 23, 2022, 06:47 PM |
| Carter Laura | Chief Scientific Officer | May 04, 2022 | Sale | $7.20 | 1,262 | 9,086 | 89,042 | May 05, 2022, 06:14 PM |
| Christian Waage | EVP, Tech Ops and Admin | Mar 23, 2022 | Sale | $8.91 | 10,722 | 95,587 | 579,008 | Mar 24, 2022, 04:57 PM |
| Hasnain Faheem | President & CEO | Mar 23, 2022 | Sale | $8.91 | 19,035 | 169,697 | 143,465 | Mar 24, 2022, 04:55 PM |
| Giraudo Bryan | COO/CFO | Mar 23, 2022 | Sale | $8.91 | 10,722 | 95,587 | 99,167 | Mar 24, 2022, 04:53 PM |
| Carter Laura | Chief Scientific Officer | Mar 16, 2022 | Sale | $8.28 | 5,002 | 41,407 | 90,304 | Mar 17, 2022, 05:03 PM |
| Peterson Caryn | EVP, Regulatory Affairs | Mar 16, 2022 | Sale | $8.28 | 6,279 | 51,978 | 66,172 | Mar 17, 2022, 05:00 PM |
| Aranda Richard | Chief Medical Officer | Mar 16, 2022 | Sale | $8.28 | 6,278 | 51,976 | 211,675 | Mar 17, 2022, 04:58 PM |
| Peterson Caryn | EVP, Regulatory Affairs | Oct 25, 2021 | Sale | $12.25 | 2,377 | 29,118 | 72,451 | Oct 26, 2021, 05:08 PM |
| Carter Laura | Chief Scientific Officer | Oct 25, 2021 | Sale | $12.25 | 2,377 | 29,118 | 95,306 | Oct 26, 2021, 05:01 PM |
| Aranda Richard | Chief Medical Officer | Oct 25, 2021 | Sale | $12.25 | 2,377 | 29,118 | 217,432 | Oct 26, 2021, 04:58 PM |
| Salter-Cid Luisa | Chief Scientific Officer | Mar 23, 2021 | Sale | $9.48 | 5,491 | 52,052 | 206,065 | Mar 25, 2021, 04:13 PM |
| Giraudo Bryan | Chief Financial Officer | Mar 23, 2021 | Sale | $9.48 | 5,490 | 52,046 | 109,889 | Mar 25, 2021, 04:11 PM |
| Christian Waage | EVP & General Counsel | Mar 23, 2021 | Sale | $9.48 | 5,490 | 52,051 | 588,199 | Mar 25, 2021, 04:09 PM |
| Christian Waage | EVP & General Counsel | Oct 14, 2020 | Buy | $9.53 | 2,500 | 23,818 | 6,954 | Oct 14, 2020, 07:29 PM |
| Hasnain Faheem | Director | Oct 14, 2020 | Buy | $10.36 | 96,520 | 999,995 | 3,478,629 | Oct 14, 2020, 07:28 PM |
| Giraudo Bryan | Chief Financial Officer | Oct 14, 2020 | Buy | $10.01 | 3,000 | 30,036 | 7,121 | Oct 14, 2020, 07:27 PM |
| Giraudo Bryan | Chief Financial Officer | Jun 23, 2020 | Buy | $12.96 | 2,000 | 25,922 | 4,121 | Jun 23, 2020, 05:01 PM |
| Dupont Jakob | Chief Medical Officer | Dec 30, 2019 | Option Exercise | $10.71 | 40,000 | 428,400 | 40,000 | Dec 31, 2019, 05:00 PM |
| Dupont Jakob | Chief Medical Officer | Dec 27, 2019 | Option Exercise | $10.71 | 1,994 | 21,356 | 1,994 | Dec 31, 2019, 05:00 PM |
| Dupont Jakob | Chief Medical Officer | Dec 27, 2019 | Sale | $15.81 | 1,994 | 31,534 | 0 | Dec 31, 2019, 05:00 PM |
| Dupont Jakob | Chief Medical Officer | Dec 30, 2019 | Sale | $15.00 | 40,000 | 600,004 | 0 | Dec 31, 2019, 05:00 PM |
| Christian Waage | EVP & General Counsel | Sep 27, 2019 | Buy | $16.65 | 1,000 | 16,654 | 4,454 | Sep 27, 2019, 10:46 AM |
| Hasnain Faheem | Director | Sep 27, 2019 | Buy | $16.80 | 10,000 | 167,980 | 3,382,109 | Sep 27, 2019, 10:41 AM |
| Gujrathi Sheila | President & CEO | Sep 27, 2019 | Buy | $16.80 | 10,000 | 167,980 | 4,048,242 | Sep 27, 2019, 10:39 AM |
| Giraudo Bryan | Chief Financial Officer | Sep 26, 2019 | Buy | $16.78 | 1,121 | 18,810 | 2,121 | Sep 26, 2019, 04:08 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 20, 2019 | Sale | $21.96 | 183,607 | 4,032,560 | 6,553,416 | Sep 23, 2019, 03:51 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 18, 2019 | Sale | $21.88 | 45,600 | 997,637 | 6,737,023 | Sep 18, 2019, 06:28 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 17, 2019 | Sale | $21.61 | 23,400 | 505,791 | 6,782,623 | Sep 18, 2019, 06:28 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 16, 2019 | Sale | $21.52 | 13,213 | 284,331 | 6,806,023 | Sep 18, 2019, 06:28 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 11, 2019 | Sale | $21.31 | 80,403 | 1,713,629 | 6,819,236 | Sep 12, 2019, 07:41 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 10, 2019 | Sale | $21.00 | 32,373 | 679,865 | 6,899,639 | Sep 12, 2019, 07:41 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 06, 2019 | Sale | $21.51 | 8,700 | 187,103 | 6,932,012 | Sep 09, 2019, 05:37 PM |
| Omega Fund V, L.P. | 10% Owner | Sep 05, 2019 | Sale | $21.60 | 12,704 | 274,434 | 6,940,712 | Sep 09, 2019, 05:37 PM |
| Salter-Cid Luisa | Chief Scientific Officer | Aug 29, 2019 | Sale | $20.09 | 26,252 | 527,319 | 124,056 | Aug 29, 2019, 06:26 PM |
| Salter-Cid Luisa | Chief Scientific Officer | Aug 28, 2019 | Sale | $19.65 | 23,748 | 466,724 | 150,308 | Aug 29, 2019, 06:26 PM |
| Giraudo Bryan | Chief Financial Officer | May 30, 2019 | Buy | $18.70 | 1,000 | 18,700 | 1,000 | Jun 03, 2019, 04:03 PM |
| Cox Russell J. | Director | Feb 12, 2019 | Buy | $16.00 | 7,200 | 115,200 | 7,200 | Feb 12, 2019, 05:40 PM |
| Christian Waage | EVP & General Counsel | Feb 12, 2019 | Buy | $16.00 | 1,550 | 24,800 | 501,498 | Feb 12, 2019, 05:36 PM |
| Giraudo Bryan | Chief Financial Officer | Feb 12, 2019 | Buy | $16.00 | 6,000 | 96,000 | 23,879 | Feb 12, 2019, 05:33 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Aranda Richard | Chief Medical Officer | 06/24/2024 | 1,260 |
| Hasnain Faheem | President & CEO | 06/21/2024 | 250,282 |
| Giraudo Bryan | COO/CFO | 06/18/2024 | 59,110 |
| Smith Robert Paul JR | Chief Commercial Officer | 06/17/2024 | 15,050 |
| Christian Waage | EVP, Tech Ops and Admin | 03/27/2024 | 7,430 |
| Giraudo Bryan | COO/CFO | 03/27/2024 | 7,431 |
| Hasnain Faheem | President & CEO | 03/27/2024 | 26,773 |
| Aranda Richard | Chief Medical Officer | 03/18/2024 | 5,342 |
| Peterson Caryn | EVP, Regulatory Affairs | 03/18/2024 | 5,343 |
| Milligan Sandra | Director | 11/15/2023 | 25,213 |
| Giraudo Bryan | COO/CFO | 11/13/2023 | 112,880 |
| Giraudo Bryan | COO/CFO | 07/24/2023 | 98,316 |
| Hasnain Faheem | President & CEO | 07/24/2023 | 983,120 |
| Christian Waage | EVP, Tech Ops and Admin | 07/24/2023 | 24,577 |
| Aranda Richard | Chief Medical Officer | 06/22/2023 | 2,340 |
| Giraudo Bryan | COO/CFO | 04/04/2023 | 56,094 |
| Christian Waage | EVP, Tech Ops and Admin | 03/20/2023 | 22,145 |
| Giraudo Bryan | COO/CFO | 03/20/2023 | 48,435 |
| Hasnain Faheem | President & CEO | 03/20/2023 | 174,486 |
| Hasnain Faheem | President & CEO | 03/22/2023 | 503,580 |
| Hasnain Faheem | President & CEO | 03/21/2023 | 322,324 |
| Carter Laura | Chief Scientific Officer | 03/16/2023 | 6,620 |
| Aranda Richard | Chief Medical Officer | 03/16/2023 | 8,304 |
| Peterson Caryn | EVP, Regulatory Affairs | 03/16/2023 | 8,305 |
| Carter Laura | Chief Scientific Officer | 10/24/2022 | 58,868 |
| Peterson Caryn | EVP, Regulatory Affairs | 10/24/2022 | 57,431 |
| Carter Laura | Chief Scientific Officer | 10/24/2022 | 58,868 |
| Aranda Richard | Chief Medical Officer | 10/24/2022 | 57,431 |
| Carter Laura | Chief Scientific Officer | 07/15/2022 | 49,994 |
| Christian Waage | EVP, Tech Ops and Admin | 07/15/2022 | 49,994 |
| Giraudo Bryan | COO/CFO | 07/15/2022 | 99,995 |
| Hasnain Faheem | President & CEO | 07/15/2022 | 999,998 |
| Carter Laura | Chief Scientific Officer | 07/01/2022 | 72,648 |
| Aranda Richard | Chief Medical Officer | 06/22/2022 | 12,233 |
| Carter Laura | Chief Scientific Officer | 05/04/2022 | 9,086 |
| Christian Waage | EVP, Tech Ops and Admin | 03/23/2022 | 95,587 |
| Hasnain Faheem | President & CEO | 03/23/2022 | 169,697 |
| Giraudo Bryan | COO/CFO | 03/23/2022 | 95,587 |
| Carter Laura | Chief Scientific Officer | 03/16/2022 | 41,407 |
| Peterson Caryn | EVP, Regulatory Affairs | 03/16/2022 | 51,978 |
| Aranda Richard | Chief Medical Officer | 03/16/2022 | 51,976 |
| Peterson Caryn | EVP, Regulatory Affairs | 10/25/2021 | 29,118 |
| Carter Laura | Chief Scientific Officer | 10/25/2021 | 29,118 |
| Aranda Richard | Chief Medical Officer | 10/25/2021 | 29,118 |
| Salter-Cid Luisa | Chief Scientific Officer | 03/23/2021 | 52,052 |
| Giraudo Bryan | Chief Financial Officer | 03/23/2021 | 52,046 |
| Christian Waage | EVP & General Counsel | 03/23/2021 | 52,051 |
| Christian Waage | EVP & General Counsel | 10/14/2020 | 23,818 |
| Hasnain Faheem | Director | 10/14/2020 | 999,995 |
| Giraudo Bryan | Chief Financial Officer | 10/14/2020 | 30,036 |
| Giraudo Bryan | Chief Financial Officer | 06/23/2020 | 25,922 |
| Dupont Jakob | Chief Medical Officer | 12/30/2019 | 428,400 |
| Dupont Jakob | Chief Medical Officer | 12/27/2019 | 21,356 |
| Dupont Jakob | Chief Medical Officer | 12/27/2019 | 31,534 |
| Dupont Jakob | Chief Medical Officer | 12/30/2019 | 600,004 |
| Christian Waage | EVP & General Counsel | 09/27/2019 | 16,654 |
| Hasnain Faheem | Director | 09/27/2019 | 167,980 |
| Gujrathi Sheila | President & CEO | 09/27/2019 | 167,980 |
| Giraudo Bryan | Chief Financial Officer | 09/26/2019 | 18,810 |
| Omega Fund V, L.P. | 10% Owner | 09/20/2019 | 4,032,560 |
| Omega Fund V, L.P. | 10% Owner | 09/18/2019 | 997,637 |
| Omega Fund V, L.P. | 10% Owner | 09/17/2019 | 505,791 |
| Omega Fund V, L.P. | 10% Owner | 09/16/2019 | 284,331 |
| Omega Fund V, L.P. | 10% Owner | 09/11/2019 | 1,713,629 |
| Omega Fund V, L.P. | 10% Owner | 09/10/2019 | 679,865 |
| Omega Fund V, L.P. | 10% Owner | 09/06/2019 | 187,103 |
| Omega Fund V, L.P. | 10% Owner | 09/05/2019 | 274,434 |
| Salter-Cid Luisa | Chief Scientific Officer | 08/29/2019 | 527,319 |
| Salter-Cid Luisa | Chief Scientific Officer | 08/28/2019 | 466,724 |
| Giraudo Bryan | Chief Financial Officer | 05/30/2019 | 18,700 |
| Cox Russell J. | Director | 02/12/2019 | 115,200 |
| Christian Waage | EVP & General Counsel | 02/12/2019 | 24,800 |
| Giraudo Bryan | Chief Financial Officer | 02/12/2019 | 96,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN GOSSAMER BIO, INC.
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| PALO ALTO INVESTORS LP | 6,277,093 | 0.66% | -1.79% | Other |
| FARALLON CAPITAL MANAGEMENT LLC | 6,130,272 | 0.03% | Exited | Event Driven, Value |
| HHLR ADVISORS, LTD. | 4,974,041 | 0.11% | No change | Other |
| PLATINUM INVESTMENT MANAGEMENT LTD | 3,524,908 | 0.13% | -24.91% | Growth At A Reasonable Price, Value |
| BLACKROCK INC. | 2,811,507 | 0.00006% | -8.99% | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 2,283,618 | 0.00018% | No change | Other |
| RENAISSANCE TECHNOLOGIES LLC | 2,046,600 | 0.00313% | 204.73% | Other |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1,366,769 | 0.02% | Exited | Growth |
| D. E. SHAW & CO., INC. | 592,889 | 0.0006% | Exited | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 98,036 | 0.0002% | Exited | Event Driven |
| TUDOR INVESTMENT CORP ET AL | 46,464 | 0.00021% | No change | Event Driven, Other |
CHANGE IN SHARES OUTSTANDING FOR GOSSAMER BIO, INC.
STOCK BUYBACKS FOR GOSSAMER BIO, INC.
Period of Report: 06/30/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
03/31/2024
5.67%
1Q
09/30/2023
23.67%
3Q
BUYBACK ANNOUNCEMENT(S) FOR GOSSAMER BIO, INC.
LOADING...